
PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.

PhaseV is a Boston-based technology company that leverages advanced causal machine learning and GenAI, augmented by an expansive data lake and real-world data (RWD), to empower biopharma sponsors and CROs with fast, accurate, and efficient clinical development decisions. The company offers a comprehensive suite of AI-powered solutions that optimize every phase of the clinical trial process, helping clients to rapidly design and implement adaptive and Bayesian clinical trials, analyze data for heterogeneous treatment effects, and improve trial planning. With over 30 biopharma and CRO customers and a commitment to transforming clinical development, PhaseV is positioned to bring new treatments to patients more efficiently.
Founded: 2023
Headquarters: Cambridge / Boston, MA
Sector: AI/ML for clinical trial optimization (biopharma/CRO)
Customers: 30–45+ biopharma and CRO customers (company claims)
Funding: Series A on 2025-05-13; total funding reported ~$65M
Clinical trial design and operations optimization, subgroup/heterogeneous treatment effect analysis, adaptive and Bayesian trial implementation.
2023
Pharmaceutical Manufacturing
Seed round participation included Viola Ventures
Series A reported as led by Accel and Insight Partners
“Participation from Accel, Insight Partners, Exor Ventures, Viola Ventures, LionBird”
| Company |
|---|
PhaseV is transforming clinical development through advanced AI and ML. With rapidly growing demand from top pharma, biotech companies, and CROs, we’re seeking a Senior Director of Business Development to help support and expand our commercial momentum as more sponsors adopt our platform to design and run smarter, faster trials. Our growth and impact have been recognized across the industry, with awards including the Biotech Breakthrough Award, TechCrunch 2025 Disruptors60, and CB Insights Digital Health 50, underscoring our innovation, real-world results, and leadership in applying AI and ML to modern clinical development.
This is a senior, externally facing role responsible for cultivating strategic partnerships, leading complex enterprise engagements, and helping shape our commercial approach as we continue to scale. You’ll work closely with the VP of Business Development and cross-functional leaders to ensure PhaseV’s technology and expertise reach the organizations driving the future of clinical innovation.
What You Bring
Preferred:
What Success Looks Like You strengthen and expand PhaseV’s growing presence across the biopharma ecosystem helping industry leaders design and execute more intelligent, efficient, and impactful clinical trials.
Additional Information